GlassScriptPhysician profile
Noah W Birch
NPI 1033451513
$8,261.98
in general payments reported to CMS, 2019-2025
8 companies · $7,650 in 2025
The $7,650 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $85.27 · 2022: $267 · 2023: $59.14 · 2024: $200 · 2025: $7,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,150 · Food and Beverage: $709 · Travel and Lodging: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,150.00 |
| Food and Beverage | $709.24 |
| Travel and Lodging | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Syndax Pharmaceuticals, INC. | $7,597.56 | 2025 | Revuforj |
| E.R. Squibb & Sons, L.L.C. | $216.32 | 2022 | |
| Sobi, INC | $200.00 | 2024 | |
| Celgene Corporation | $81.83 | 2023-2025 | Reblozyl, Pomalyst |
| Epizyme, INC. | $67.17 | 2021 | |
| Genentech USA, INC. | $51.29 | 2021-2022 | |
| Beigene USA, INC. | $29.85 | 2025 | Tevimbra, Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $17.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noah Birch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.